Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease symbols : INCY save search
Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
Published: 2024-02-27 (Crawled : 23:00) - biospace.com/
SNDX | $20.82 1.61% 1.59% 850K
|
Health Technology
|
| O: 0.88%
H: 1.12%
C: -0.73%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.2%
H: 1.37%
C: 0.58%
drug disease review food treatment grants
The Evolving Market Dynamics of Factor-based Bleeding Disorders: Hemophilia A, Hemophilia B, and Von Willebrand Disease | Key Analysis by DelveInsight
Published: 2023-10-09 (Crawled : 21:00) - prnewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: 0.09%
H: 1.41%
C: 0.94%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.67%
H: 0.56%
C: -0.01%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.51%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.48%
H: 1.39%
C: 0.51%
ALPN | $64.535 0.16% 0.16% 4M
|
Health Technology
|
| O: -1.07%
H: 0.0%
C: -6.9%
bleeding disease market
Graft Versus Host Disease Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Assesses DelveInsight | Key Companies - Glia, Incyte, Novartis, GlaxoSmithKline, Pfizer, BMS, Roche, AstraZeneca, Sanofi
Published: 2023-09-27 (Crawled : 21:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.28%
H: 0.0%
C: -0.06%
MCRB | $0.5671 -2.93% -3.02% 3.7M
|
Health Technology
|
| O: 0.42%
H: 0.63%
C: -0.42%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.61%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.03%
H: 0.34%
C: -0.88%
disease companies sanofi growth market
Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease
Published: 2023-07-24 (Crawled : 11:00) - prnewswire.com
SNDX | $20.82 1.61% 1.59% 850K
|
Health Technology
|
| O: 8.18%
H: 2.39%
C: -5.35%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.17%
H: 0.37%
C: -1.24%
agave-201 disease positive topline trial results
Innovent Announces First Participant Dosed in Phase 3 Study (RESTORE) of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Eye Disease
Published: 2023-05-08 (Crawled : 00:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.38%
H: 2.06%
C: 1.53%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.59%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.03%
H: 0.17%
C: -1.19%
ibi311 disease thyroid eye study
Innovent and LG Chem Announce Strategic Collaboration for Tigulixostat, a Novel Non-Purine Xanthine Oxidase Inhibitor for the Treatment of Gout Disease
Published: 2022-12-15 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.78%
H: 0.92%
C: -0.18%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.83%
H: 0.66%
C: 0.3%
treatment disease collaboration
Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology
Published: 2022-12-05 (Crawled : 12:20) - biospace.com/
SNDX | $20.82 1.61% 1.59% 850K
|
Health Technology
|
| O: -0.28%
H: 4.28%
C: 1.76%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.43%
H: 2.17%
C: 1.58%
pharmaceuticals disease phase 1
Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease
Published: 2022-05-05 (Crawled : 10:00) - biospace.com/
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.39%
H: 0.15%
C: -1.07%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 3.73%
H: 0.09%
C: -3.98%
jakavi treatment disease approval
Cold Agglutinin Disease Market to Exhibit Massive Growth at a CAGR of 28% in the 7MM for the Study Period of 2019-32 | DelveInsight
Published: 2022-03-30 (Crawled : 16:00) - prnewswire.com
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
|
| O: 4.29%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.94%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.05%
H: 0.63%
C: -0.1%
disease growth market
Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi®) for the Treatment of Acute and Chronic Graft-Versus-Host Disease
Published: 2022-03-25 (Crawled : 14:00) - biospace.com/
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.33%
H: 0.29%
C: 0.01%
jakavi treatment disease positive chmp
Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases
Published: 2021-09-27 (Crawled : 12:00) - biospace.com/
SNDX | $20.82 1.61% 1.59% 850K
|
Health Technology
|
| O: 6.0%
H: 0.86%
C: -0.15%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.89%
H: 0.54%
C: 0.51%
disease collaboration commercialization
Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)
Published: 2021-09-22 (Crawled : 18:00) - biospace.com/
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.17%
H: 0.08%
C: -0.47%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -3.87%
H: 1.0%
C: -4.83%
disease treatment fda fda approval approval
Global Graft Versus Host Disease (GVHD): Market Size from 2018 to 2030 and Overview of Treatment Practices and Emerging Drugs
Published: 2021-06-29 (Crawled : 16:00) - prnewswire.com
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.47%
H: 0.89%
C: -0.6%
disease treatment drug
Incyte Announces U.S. FDA Has Extended the sNDA Review Period for Ruxolitinib (Jakafi®) in Chronic Graft-Versus-Host Disease (GVHD)
Published: 2021-06-08 (Crawled : 12:00) - biospace.com/
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.84%
H: 0.01%
C: -0.81%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.9%
H: 0.49%
C: -1.25%
disease fda
Global Kinase Inhibitors in Autoimmune Diseases Market to Continue on Growth Trajectory with 19.17% CAGR During the Study Period (2018-2030), Asserts DelveInsight
Published: 2021-04-19 (Crawled : 17:00) - prnewswire.com
MDT | $79.48 0.37% -0.29% 6.7M
|
Health Technology
|
| O: -0.44%
H: 0.74%
C: 0.61%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.16%
H: 0.38%
C: 0.12%
EW | $85.94 -0.59% 0.0% 3.9M
|
Health Technology
|
| O: -0.73%
H: 0.75%
C: 0.22%
BSX | $67.33 -0.13% -0.31% 7M
|
Health Technology
|
| O: -0.29%
H: 0.44%
C: 0.22%
NUVA | $39.75 -2.24% -2.29% 0
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: -0.32%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.13%
H: 1.12%
C: -0.14%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: 0.58%
H: 0.21%
C: -0.98%
disease growth
Incyte Announces Acceptance and Priority Review of sNDA for Jakafi® (ruxolitinib) as a Treatment for Patients with Chronic Graft-Versus-Host Disease
Published: 2021-02-22 (Crawled : 16:00) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.65%
H: 0.59%
C: -0.12%
disease treatment
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.